drug · small molecule

SUBOXONE

updated 2mo ago

by $INDV Indivior Pharmaceuticals, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for opioid dependence and drug dependence and 1 investigational indication.

targets

Kappa-type opioid receptorMu-type opioid receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SUBOXONE

trade names

Belbuca, Buprenex, Buprenorphine hydrochloride, Buprenorphine hydrochloride component of bunavail, Buprenorphine hydrochloride component of cassipa, Buprenorphine hydrochloride component of suboxone

generic

BUPRENORPHINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action SUBOXONE sublingual film contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

indication

1 INDICATIONS AND USAGE SUBOXONE sublingual film is indicated for treatment of opioid dependence. SUBOXONE sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. SUBOXONE® sublingual film contains buprenorphine, a partial‐opioid agonist, and naloxone, an opioid antagonist, and is indicated for treatment of opioid dependence. ( 1 ) SUBOXONE sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

SUBOXONE

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying SUBOXONE